FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208045993> ?p ?o ?g. }

• W3208045993 endingPage "1932" @default.
• W3208045993 startingPage "1932" @default.
• W3208045993 abstract "Abstract CAR-T therapies represent a novel advance in oncology, albeit at list prices that exceed $373,000 (and that does not capture their total cost to the healthcare system). Since initial product approval in 2017, stakeholders and observers have attempted to investigate clinical and financial impacts of CAR-T therapies, and potential approaches to optimizing access and use by eligible patients. Most existing research is from a single stakeholder perspective - patients, providers, or payers - limiting the ability to draw broader conclusions on trends and offer prospective recommendations. To address this knowledge gap, we sought to identify and describe critical success factors for optimal delivery of CAR-T therapies. We undertook a qualitative study based on interviews with multiple US-based stakeholders including clinicians, financial and operations staff, and payer-insurers. Interviewees--which included oncologists (n=6), facility financial and operational personnel (n=4), and coverage and reimbursement decision-makers from US health plans (n=3)--completed structured, live, hour-long, interviews covering clinical, administrative, and general topics on patient access to CAR-T therapies. All clinicians had experience with ≥1 FDA-approved CAR-T therapies in both registered clinical trials and clinical practice; financial and operational personnel were affiliated with the same facilities as the clinicians, and also had real-world experience with these therapies; payer representatives were directors from a large national commercial plan, regional integrated delivery network, and a Medicare administrative contractor, respectively. Consensus facility feedback (i.e., clinicians, operational personnel) was that CAR-T is effective, and that their administrative processes had been optimized through care team coordination and experience-based efficiencies; in contrast, 2 of 3 payer interviewees expressed that, while CAR-T therapies have shown efficacy, their real-world benefits and applicability are less well-defined. Facility interviewees noted that: (1) reimbursement from commercial insurers is higher than from Medicare, with the latter associated with per-patient net-neutral or negative margins; (2) when possible, differential reimbursement between inpatient and outpatient settings may drive patient management towards outpatient care; and (3) negative-margin cases are currently deemed acceptable due to nonclinical factors (i.e., competitive pressure within a geographic region, anticipated branding/marketing value) and relatively small treated populations. From payer interviewees, CAR-T cost and perceived cost-to-value have made health plans more receptive to considering outcomes-based contracting, capitated provider payments, or other mitigation methods. Left unoptimized, these factors may adversely impact patient access to, and long-term provider attractiveness of, CAR-T therapies. All interviewees agreed that as the CAR-T marketplace grows, a strong preference exists for manufacturers to develop and communicate for their therapies durable outcomes data, clear and comprehensive reimbursement information, and competitive pricing. With the potential for many approved products in a single indication, and/or a single approval for indications with relatively large eligible patient populations, interviewees also conveyed interest in compelling health economic data. Facility interviewees also acknowledged that if it remains an overall net-negative margin service, new providers will be less able to start CAR-T programs and smaller programs may encounter sustainability issues, collectively jeopardizing patient access to these life-changing therapies. Overall, findings from this study suggest that during the continued maturation of the landscape, stakeholders will need to be proactive to ensure that CAR T-cell therapies can be maintained amidst financial and operational pressures. Several CAR-T therapy options for multiple myeloma are on the immediate horizon, likely increasing demand among eligible patients. Accordingly, the need to link real-world evidence of the clinical value and institutional investment burden of these therapies to reimbursement is imperative, both to insulate payers and enable clinicians to provide innovative therapies. Figure 1 Figure 1. Disclosures Faber: Amgen: Honoraria; Adaptive: Honoraria; Cardinal Health: Honoraria; Celgene: Honoraria; Astra Zeneca: Honoraria; GlaxoSmith Kline: Honoraria; Janssen: Honoraria; Juno: Honoraria; Karyopharm: Honoraria; Kite: Honoraria; Takeda: Honoraria; Sanofi Genzyme: Honoraria. Hunter: BMS: Consultancy, Honoraria; Kite: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria. Deol: Kite, a Gilead Company: Consultancy. Crivera: Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Riccobono: Legend Biotech: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Garrett: Legend Biotech USA: Current Employment. Jackson: Memorial Sloan Kettering Cancer Center: Consultancy; Janssen: Current Employment. Fowler: Amgen: Ended employment in the past 24 months; Janssen: Current Employment. Berger: Janssen Scientific Affairs: Consultancy, Research Funding. Lorden: Janssen Scientific Affairs: Consultancy, Research Funding. Stewart: Janssen Scientific Affairs: Consultancy, Research Funding." @default.
• W3208045993 created "2021-11-08" @default.
• W3208045993 creator A5003267064 @default.
• W3208045993 creator A5009026971 @default.
• W3208045993 creator A5010508254 @default.
• W3208045993 creator A5017584580 @default.
• W3208045993 creator A5023980350 @default.
• W3208045993 creator A5043663144 @default.
• W3208045993 creator A5051092535 @default.
• W3208045993 creator A5061926992 @default.
• W3208045993 creator A5067025516 @default.
• W3208045993 creator A5086470642 @default.
• W3208045993 creator A5087850384 @default.
• W3208045993 creator A5088826060 @default.
• W3208045993 date "2021-11-05" @default.
• W3208045993 modified "2023-09-27" @default.
• W3208045993 title "Considerations for Optimal Administration of Chimeric Antigen Receptor (CAR) T-Cell Therapy Programs: A Multi-Stakeholder Qualitative Analysis" @default.
• W3208045993 doi "https://doi.org/10.1182/blood-2021-145943" @default.
• W3208045993 hasPublicationYear "2021" @default.
• W3208045993 type Work @default.
• W3208045993 sameAs 3208045993 @default.
• W3208045993 citedByCount "2" @default.
• W3208045993 countsByYear W32080459932022 @default.
• W3208045993 countsByYear W32080459932023 @default.
• W3208045993 crossrefType "journal-article" @default.
• W3208045993 hasAuthorship W3208045993A5003267064 @default.
• W3208045993 hasAuthorship W3208045993A5009026971 @default.
• W3208045993 hasAuthorship W3208045993A5010508254 @default.
• W3208045993 hasAuthorship W3208045993A5017584580 @default.
• W3208045993 hasAuthorship W3208045993A5023980350 @default.
• W3208045993 hasAuthorship W3208045993A5043663144 @default.
• W3208045993 hasAuthorship W3208045993A5051092535 @default.
• W3208045993 hasAuthorship W3208045993A5061926992 @default.
• W3208045993 hasAuthorship W3208045993A5067025516 @default.
• W3208045993 hasAuthorship W3208045993A5086470642 @default.
• W3208045993 hasAuthorship W3208045993A5087850384 @default.
• W3208045993 hasAuthorship W3208045993A5088826060 @default.
• W3208045993 hasConcept C142724271 @default.
• W3208045993 hasConcept C144133560 @default.
• W3208045993 hasConcept C160735492 @default.
• W3208045993 hasConcept C162324750 @default.
• W3208045993 hasConcept C17744445 @default.
• W3208045993 hasConcept C201305675 @default.
• W3208045993 hasConcept C2779703844 @default.
• W3208045993 hasConcept C39549134 @default.
• W3208045993 hasConcept C50522688 @default.
• W3208045993 hasConcept C535046627 @default.
• W3208045993 hasConcept C71924100 @default.
• W3208045993 hasConceptScore W3208045993C142724271 @default.
• W3208045993 hasConceptScore W3208045993C144133560 @default.
• W3208045993 hasConceptScore W3208045993C160735492 @default.
• W3208045993 hasConceptScore W3208045993C162324750 @default.
• W3208045993 hasConceptScore W3208045993C17744445 @default.
• W3208045993 hasConceptScore W3208045993C201305675 @default.
• W3208045993 hasConceptScore W3208045993C2779703844 @default.
• W3208045993 hasConceptScore W3208045993C39549134 @default.
• W3208045993 hasConceptScore W3208045993C50522688 @default.
• W3208045993 hasConceptScore W3208045993C535046627 @default.
• W3208045993 hasConceptScore W3208045993C71924100 @default.
• W3208045993 hasIssue "Supplement 1" @default.
• W3208045993 hasLocation W32080459931 @default.
• W3208045993 hasOpenAccess W3208045993 @default.
• W3208045993 hasPrimaryLocation W32080459931 @default.
• W3208045993 hasRelatedWork W1500763845 @default.
• W3208045993 hasRelatedWork W1754975726 @default.
• W3208045993 hasRelatedWork W2015194088 @default.
• W3208045993 hasRelatedWork W2097566776 @default.
• W3208045993 hasRelatedWork W2166521090 @default.
• W3208045993 hasRelatedWork W2269415488 @default.
• W3208045993 hasRelatedWork W2319748522 @default.
• W3208045993 hasRelatedWork W2464778730 @default.
• W3208045993 hasRelatedWork W2567549657 @default.
• W3208045993 hasRelatedWork W3112813433 @default.
• W3208045993 hasVolume "138" @default.
• W3208045993 isParatext "false" @default.
• W3208045993 isRetracted "false" @default.
• W3208045993 magId "3208045993" @default.
• W3208045993 workType "article" @default.